Top-Rated StocksTop-RatedNASDAQ:INSM Insmed (INSM) Stock Forecast, Price & News $18.79 +0.09 (+0.48%) (As of 05/26/2023 08:47 PM ET) Add Compare Share Share Today's Range$18.59▼$19.0150-Day Range$16.26▼$20.3152-Week Range$16.04▼$28.94Volume572,700 shsAverage Volume1.22 million shsMarket Capitalization$2.56 billionP/E RatioN/ADividend YieldN/APrice Target$43.33 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Insmed MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside130.6% Upside$43.33 Price TargetShort InterestBearish6.79% of Shares Sold ShortDividend StrengthN/ASustainability-1.29Upright™ Environmental ScoreNews Sentiment0.56Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($4.50) to ($3.94) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.08 out of 5 starsMedical Sector504th out of 1,010 stocksPharmaceutical Preparations Industry242nd out of 494 stocks 3.5 Analyst's Opinion Consensus RatingInsmed has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 11 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $43.33, Insmed has a forecasted upside of 130.6% from its current price of $18.79.Amount of Analyst CoverageInsmed has received no research coverage in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted6.79% of the outstanding shares of Insmed have been sold short.Short Interest Ratio / Days to CoverInsmed has a short interest ratio ("days to cover") of 7.8.Change versus previous monthShort interest in Insmed has recently increased by 1.65%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldInsmed does not currently pay a dividend.Dividend GrowthInsmed does not have a long track record of dividend growth. Previous Next 4.4 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreInsmed has received a 65.67% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Aminoglycosides", "Clinical research services for physical health", and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Insmed is -1.29. Previous Next 2.0 News and Social Media Coverage News SentimentInsmed has a news sentiment score of 0.56. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.77 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Insmed this week, compared to 3 articles on an average week.MarketBeat Follows6 people have added Insmed to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Insmed insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.30% of the stock of Insmed is held by insiders.Percentage Held by Institutions92.83% of the stock of Insmed is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Insmed are expected to grow in the coming year, from ($4.50) to ($3.94) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Insmed is -4.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Insmed is -4.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioInsmed has a P/B Ratio of 28.91. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Insmed (NASDAQ:INSM) StockInsmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Insmed's earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension.Read More Receive INSM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Insmed and its competitors with MarketBeat's FREE daily newsletter. Email Address INSM Stock News HeadlinesMay 24, 2023 | americanbankingnews.comInsmed (NASDAQ:INSM) Rating Lowered to Sell at StockNews.comMay 22, 2023 | finance.yahoo.comInsmed Presents Range of New Study Findings at American Thoracic Society 2023 International ConferenceMay 29, 2023 | Behind the Markets (Ad)WARNING TO ALL U.S. INVESTORSMay 16, 2023... The Day That Will Financially Paralyze 181 Million American Investors... Here are 3 steps to prepare yourself >>>May 21, 2023 | americanbankingnews.comInsmed Incorporated (NASDAQ:INSM) Receives $43.33 Consensus PT from BrokeragesMay 13, 2023 | americanbankingnews.comQ2 2023 EPS Estimates for Insmed Incorporated (NASDAQ:INSM) Reduced by AnalystMay 12, 2023 | americanbankingnews.comInsmed (NASDAQ:INSM) Upgraded by StockNews.com to "Hold"May 10, 2023 | markets.businessinsider.comAnalysts Are Bullish on These Healthcare Stocks: Insmed (INSM), Liquidia Technologies (LQDA)May 10, 2023 | markets.businessinsider.comH.C. Wainwright Reaffirms Their Buy Rating on Insmed (INSM)May 29, 2023 | Behind the Markets (Ad)Buy THIS stock before Taiwan is attacked... If the United States goes to war with another nuclear armed superpower, this could have a devastating impact on your retirement portfolio. Now, even Taiwan's own foreign minister is saying that China is on the cusp of a full scale invasion. But the good news is, if China invades Taiwan, there is a way to protect yourself.May 10, 2023 | msn.comHC Wainwright & Co. Reiterates Insmed (INSM) Buy RecommendationMay 9, 2023 | americanbankingnews.comInsmed Incorporated Forecasted to Post FY2025 Earnings of ($2.49) Per Share (NASDAQ:INSM)May 8, 2023 | finance.yahoo.comInsmed Unveils New Research Platforms and Capabilities at Investor and Analyst Event, "The Future of Rare at Insmed: Functional Genes, AI-Enhanced Proteins, Glowing Algae, and More"May 4, 2023 | finance.yahoo.comInsmed Reports First Quarter 2023 Financial Results and Provides Business UpdateMay 3, 2023 | americanbankingnews.comInsmed (INSM) to Release Quarterly Earnings on ThursdayApril 28, 2023 | americanbankingnews.comBrokerages Set Insmed Incorporated (NASDAQ:INSM) PT at $43.33April 24, 2023 | finance.yahoo.comInsmed to Host Investor and Analyst Event on May 8, 2023April 20, 2023 | finance.yahoo.comInsmed to Host First Quarter 2023 Financial Results Conference Call on Thursday, May 4, 2023April 20, 2023 | americanbankingnews.comStockNews.com Downgrades Insmed (NASDAQ:INSM) to SellApril 18, 2023 | finance.yahoo.comInsmed Incorporated's (NASDAQ:INSM) Business Is Trailing The Industry But Its Shares Aren'tApril 7, 2023 | americanbankingnews.comInsmed (NASDAQ:INSM) Downgraded to Sell at StockNews.comApril 7, 2023 | americanbankingnews.comInsmed (NASDAQ:INSM) and Shattuck Labs (NASDAQ:STTK) Financial SurveyApril 4, 2023 | americanbankingnews.comInsmed Incorporated (NASDAQ:INSM) Short Interest UpdateApril 3, 2023 | americanbankingnews.comInsmed Incorporated (NASDAQ:INSM) Given Consensus Recommendation of "Moderate Buy" by BrokeragesMarch 31, 2023 | finance.yahoo.comInsmed Completes Enrollment of Adult Patients in Phase 3 ASPEN Study of Brensocatib in BronchiectasisMarch 31, 2023 | americanbankingnews.comInsmed (NASDAQ:INSM) Raised to "Hold" at StockNews.comMarch 24, 2023 | finance.yahoo.comInsmed to Present New Clinical, Pre-Clinical, and Real-World Data in Serious and Rare Lung Diseases at the American Thoracic Society 2023 International ConferenceMarch 23, 2023 | finance.yahoo.comA Look At The Fair Value Of Insmed Incorporated (NASDAQ:INSM)See More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive INSM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Insmed and its competitors with MarketBeat's FREE daily newsletter. Email Address INSM Company Calendar Last Earnings5/04/2023Today5/29/2023Next Earnings (Estimated)8/03/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:INSM CUSIPN/A CIK1104506 Webwww.insmed.com Phone908-977-9900Fax732-438-0381Employees373Year FoundedN/APrice Target and Rating Average Stock Price Forecast$43.33 High Stock Price Forecast$53.00 Low Stock Price Forecast$28.00 Forecasted Upside/Downside+130.6%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage11 Analysts Profitability EPS (Most Recent Fiscal Year)($4.27) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-481,530,000.00 Net Margins-212.33% Pretax Margin-211.76% Return on Equity-3,789.32% Return on Assets-41.78% Debt Debt-to-Equity Ratio13.13 Current Ratio6.01 Quick Ratio5.63 Sales & Book Value Annual Sales$245.36 million Price / Sales10.45 Cash FlowN/A Price / Cash FlowN/A Book Value$0.65 per share Price / Book28.91Miscellaneous Outstanding Shares136,430,000Free Float130,566,000Market Cap$2.56 billion OptionableOptionable Beta1.53 Social Links Key ExecutivesMr. William H. Lewis J.D. (Age 50)Pres, CEO & Chairman Mr. Paolo Tombesi (Age 55)Chief Financial Officer Ms. Christine A. Pellizzari J.D. (Age 51)Chief Legal Officer & Corp. Sec. Mr. Roger Adsett (Age 50)Chief Commercial Officer Dr. Paul D. Streck (Age 55)Advisor Key CompetitorsMirati TherapeuticsNASDAQ:MRTXXenon PharmaceuticalsNASDAQ:XENECorcept TherapeuticsNASDAQ:CORTRevance TherapeuticsNASDAQ:RVNCSchrödingerNASDAQ:SDGRView All CompetitorsInsiders & InstitutionsProShare Advisors LLCSold 3,232 shares on 5/26/2023Ownership: 0.019%New York State Common Retirement FundSold 21,782 shares on 5/18/2023Ownership: 0.052%Long Focus Capital Management LLCBought 36,649 shares on 5/17/2023Ownership: 0.265%Thrivent Financial for LutheransBought 163,160 shares on 5/17/2023Ownership: 0.120%AQR Capital Management LLCSold 578 shares on 5/16/2023Ownership: 0.025%View All Insider TransactionsView All Institutional Transactions INSM Stock - Frequently Asked Questions Should I buy or sell Insmed stock right now? 11 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Insmed in the last twelve months. There are currently 11 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" INSM shares. View INSM analyst ratings or view top-rated stocks. What is Insmed's stock price forecast for 2023? 11 brokers have issued 1-year price targets for Insmed's stock. Their INSM share price forecasts range from $28.00 to $53.00. On average, they predict the company's stock price to reach $43.33 in the next year. This suggests a possible upside of 130.6% from the stock's current price. View analysts price targets for INSM or view top-rated stocks among Wall Street analysts. How have INSM shares performed in 2023? Insmed's stock was trading at $19.98 on January 1st, 2023. Since then, INSM stock has decreased by 6.0% and is now trading at $18.79. View the best growth stocks for 2023 here. When is Insmed's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 3rd 2023. View our INSM earnings forecast. How were Insmed's earnings last quarter? Insmed Incorporated (NASDAQ:INSM) announced its quarterly earnings results on Thursday, May, 4th. The biopharmaceutical company reported ($1.17) earnings per share for the quarter, missing the consensus estimate of ($1.08) by $0.09. The biopharmaceutical company had revenue of $65.20 million for the quarter, compared to analyst estimates of $63.93 million. Insmed had a negative net margin of 212.33% and a negative trailing twelve-month return on equity of 3,789.32%. The company's revenue was up 22.8% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.80) earnings per share. What ETFs hold Insmed's stock? ETFs with the largest weight of Insmed (NASDAQ:INSM) stock in their portfolio include Virtus LifeSci Biotech Products ETF (BBP), SPDR S&P Biotech ETF (XBI), Direxion Daily S&P Biotech Bull 3x Shares (LABU), Principal Healthcare Innovators ETF (BTEC), JPMorgan BetaBuilders U.S. Small Cap Equity ETF (BBSC), iShares Biotechnology ETF (IBB), Vanguard Russell 2000 Growth ETF (VTWG) and Invesco Nasdaq Biotechnology ETF (IBBQ). What guidance has Insmed issued on next quarter's earnings? Insmed issued an update on its FY 2023 earnings guidance on Thursday, May, 4th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $285.00 million-$300.00 million, compared to the consensus revenue estimate of $293.16 million. What is Will Lewis' approval rating as Insmed's CEO? 14 employees have rated Insmed Chief Executive Officer Will Lewis on Glassdoor.com. Will Lewis has an approval rating of 78% among the company's employees. What other stocks do shareholders of Insmed own? Based on aggregate information from My MarketBeat watchlists, some companies that other Insmed investors own include Gilead Sciences (gild), AbbVie (ABBV), Johnson & Johnson (JNJ), NVIDIA (NVDA), Micron Technology (MU), ACADIA Pharmaceuticals (ACAD), OPKO Health (OPK), Pfizer (PFE), Alibaba Group (BABA) and Geron (GERN). What is Insmed's stock symbol? Insmed trades on the NASDAQ under the ticker symbol "INSM." Who are Insmed's major shareholders? Insmed's stock is owned by a variety of institutional and retail investors. Top institutional investors include Price T Rowe Associates Inc. MD (7.32%), Palo Alto Investors LP (4.32%), Pictet Asset Management SA (2.88%), William Blair Investment Management LLC (2.72%), Suvretta Capital Management LLC (2.15%) and Geode Capital Management LLC (1.92%). Insiders that own company stock include Alfred Altomari, Christine A Pellizzari, David R Brennan, John Drayton Wise, John Soriano, Martina MD Flammer, Melvin Md Sharoky, Michael Alexander Smith, Orlov S Nicole Schaeffer, Roger Adsett, Sara Bonstein and William Lewis. View institutional ownership trends. How do I buy shares of Insmed? Shares of INSM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Insmed's stock price today? One share of INSM stock can currently be purchased for approximately $18.79. How much money does Insmed make? Insmed (NASDAQ:INSM) has a market capitalization of $2.56 billion and generates $245.36 million in revenue each year. The biopharmaceutical company earns $-481,530,000.00 in net income (profit) each year or ($4.27) on an earnings per share basis. How many employees does Insmed have? The company employs 373 workers across the globe. How can I contact Insmed? Insmed's mailing address is 700 US Highway 202/206, Bridgewater NJ, 08807. The official website for the company is www.insmed.com. The biopharmaceutical company can be reached via phone at 908-977-9900, via email at investor.relations@insmed.com, or via fax at 732-438-0381. This page (NASDAQ:INSM) was last updated on 5/29/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Insmed Incorporated Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.